Boston Scientific stock rises as BSX teases new pain-therapy data while FDA stent alert hangs over shares
Boston Scientific shares rose about 3.1% to $90.77 Tuesday after the company announced new long-term neuromodulation data for presentation at the NANS meeting in Las Vegas. Investors weighed the news alongside concerns over an FDA alert on AXIOS stents and the $14.5 billion Penumbra acquisition.